- Home
- REFI vs CNTX Comparison
REFI vs CNTX Comparison
Compare REFI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | CNTX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6M | 283.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REFI | CNTX |
|---|---|---|
| Price | $11.96 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 133.8K | ★ 916.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $17.47 | N/A |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | $50.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.74 | $0.49 |
| 52 Week High | $15.20 | $3.62 |
Technical Indicators
Market Signals| Indicator | REFI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 47.48 |
| Support Level | $11.90 | $2.10 |
| Resistance Level | $12.47 | $2.56 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 57.53 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.